However, low-dose methotrexate failed to reduce the levels of CRP, IL-6, and IL-1b in a double-blind placebo-controlled randomized trial that included more than 4500 patients with established CAD and metabolic syndrome or diabetes. The gene discussed is CRP; the disease is coronary artery disorder.